Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 10, 2000, Pages 1249-1258

  Kahrilas, P J ^a,b,c,d,e,f   Falk, G W ^a,b,c,d,e,f   Johnson, D A ^a,b,c,d,e,f   Schmitt, C ^a,b,c,d,e,f   Collins, D W ^a,b,c,d,e,f   Whipple, J ^a,b,c,d,e,f   D'Amico, D ^a,b,c,d,e,f   Hamelin, B ^a,b,c,d,e,f   Joelsson, B ^a,b,c,d,e,f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Eastern Virginia School of Medicine   (United States)

^d UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

^e Western States Clinical Research   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS;

ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; FEMALE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 0033785204     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00856.x     Document Type: Article

References (40)

1. Gastroesophageal reflux disease (Hiatal hernia and heartburn)
2. Current diagnosis and treatment of gastroesophageal reflux disease
3. Gastroesophageal reflux disease
4. The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving forward to new concepts
5. Medical treatment of gastroesophageal reflux in the managed care environment
6. The economics of therapy of gastroesophageal reflux disease
7. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases
8. Epidemiology and natural history of gastro-oesophageal reflux disease
9. The pathogenesis of gastroesophageal reflux disease: The relationship between epithelial defense, dysmotility, and acid exposure
10. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn
11. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
12. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis
13. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease
14. Progress with proton pump inhibition
15. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders
16. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview
17. An evidence-based appraisal of reflux disease management - The Genval Workshop report
18. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. Multicenter Study
19. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
20. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders
21. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group
22. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis
23. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease
24. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
25. Interobserver and intraobserver variation in endoscopic assessment of GERD using the 'Los Angeles' classification
26. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group
27. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
28. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial
29. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II III and IVa (a Dutch multicentre trial). Dutch Study Group
30. A comparison of omeprazole MUPS 20 MG, Lansoprazole 30 mg and pantoprazole 40 mg in the treatment of reflux oesophagitis: A multicenter trial
31. Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors (PPIs): A meta-analysis of comparative trials
32. Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group
33. Rabeprazole is comparable in efficacy to omeprazole in erosive GERD and provides more rapid heartburn relief
34. Rabeprazole is as effective as omeprazole in preventing relapse of erosive or ulcerative GERD in the second year of treatment
35. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study
36. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial
37. Pantoprazole (PANTO) 20 mg is as effective as omeprazole (OME) 20 mg in patients with mild gastroesophageal reflux disease (GERD)
38. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis
39. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease